On 25 September the FDA approved tavapadon (Juvmo) to improve motor function in adults with Parkinson’s disease. Juvmo is a D1/D5 partial agonist engineered to preferentially target D1 receptors, aiming to reduce non‑motor side effects and provide more sustained symptom control. Approval was supported by positive Phase III TEMPO results showing motor improvements and reduced motor fluctuations when combined with levodopa. AbbVie acquired the drug via its $8.7bn purchase of Cerevel and analysts view Juvmo and Vyalev as potential growth drivers amid calls for better biomarkers to advance disease‑modifying therapies.
AbbVie’s Juvmo (tavapadon) Wins FDA Approval — A More Targeted Dopamine Therapy For Parkinson’s
Juvmo offers patients with Parkinson's a new option to control motor symptoms. Credit: Nicole Rerk / Shutterstock.com.
On 25 September the US Food and Drug Administration approved tavapadon, which AbbVie will market as Juvmo, for improving motor function in adults with Parkinson’s disease. The approval follows AbbVie’s acquisition of Cerevel Therapeutics and underscores the strategic value of that deal for the company’s neurology portfolio.
How Juvmo Works
Juvmo is a dopamine‑based partial agonist at D1 and D5 receptors, designed to preferentially engage D1 receptors that are closely linked to motor control. Compared with older treatments such as levodopa that interact with multiple dopamine receptor subtypes, Juvmo’s selective profile aims to limit non‑motor side effects associated with D2 and D3 activation. Its extended half‑life is intended to offer more sustained symptom control.
Clinical Evidence
The FDA’s decision was supported by positive results from the Phase III TEMPO programme (NCT04201093; NCT04223193; NCT04542499; NCT04760769), which evaluated tavapadon under both flexible and fixed dosing regimens across patients with varying stages and presentations of Parkinson’s disease. Published data show significant improvements in motor symptoms in TEMPO‑1 and TEMPO‑2, and a significant reduction in motor fluctuations when tavapadon was added to levodopa versus levodopa alone in TEMPO‑3.
Commercial Context
AbbVie acquired Juvmo through its $8.7 billion takeover of Cerevel Therapeutics in 2024. Analysts, including William Blair in April 2026, see Juvmo alongside AbbVie’s continuous dopamine replacement therapy, Vyalev (foscarbidopa/foslevodopa), as potential mid‑to‑long‑term commercial growth drivers for the company.
Expert Perspective And Outlook
David Dexter, head of research at Parkinson’s UK, welcomed the arrival of a more selective dopamine agent but stressed that the field’s biggest leap would be the arrival of disease‑modifying therapies (DMTs). He noted two major obstacles: the heterogeneity of Parkinson’s disease and a lack of standardized, objective clinical endpoints to demonstrate disease modification. Dexter and others advocate for wider use of digital, blood, and imaging biomarkers to produce more objective, reproducible measures in trials.
A recent GlobalData report projects the Parkinson’s therapeutics market in the seven major markets (US, France, Germany, Italy, Spain, UK and Japan) could reach about $7 billion by 2033, highlighting continued commercial interest in new and improved treatments.
Bottom line: Juvmo provides a targeted, next‑generation dopamine approach with supportive Phase III data and commercial momentum, but broader progress in Parkinson’s will depend on better biomarkers and successful development of disease‑modifying strategies.
Help us improve.
